Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma.

Objectives: To assess the long-term oncological efficacy of radiofrequency ablation (RFA) for treatment of renal cell carcinoma (RCC).

Methods: In this institutional review board-approved, retrospective study, the records and imaging studies for all RCC patients treated with percutaneous RFA before 2005 were reviewed and analyzed.

Results: A total of 48 RCCs in 41 patients were treated with RFA.

Percutaneous radiofrequency ablation does not affect glomerular filtration rate.

Purpose: To study short- and intermediate-term global renal function in patients undergoing a single percutaneous radiofrequency ablation (pRFA) for a solitary renal parenchymal tumor.

Materials And Methods: We reviewed the records of 62 patients who underwent a single pRFA for solitary renal parenchymal tumor. We used the abbreviated Modified Diet for Renal Disease equation to calculate baseline, 1-month, and 1-year glomerular filtration rate (GFR).

Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas.

Objective: A single institution's experience with CT-guided percutaneous radiofrequency ablation of biopsy-proven renal cell carcinomas (RCCs) was studied to determine the disease-free survival and complication rate.

Materials And Methods: Data from 125 RCCs in 104 patients treated with curative intent was reviewed. Radiofrequency ablation treatments were performed using conscious sedation and local anesthesia.